이수진 교수
#비뇨기계암#식도암#위암#유방암#혈액질환#희귀암
|
학력
2013 | 성균관대학교 의학박사
2005 | 성균관대학교 의과대학 졸업
2005 | 성균관대학교 의과대학 졸업
경력
2016-2019 | 삼성서울병원 혈액종양내과 진료조교수
2013-2016 | 삼성서울병원 혈액종양내과 임상전임강사
2012-2013 | 삼성서울병원 혈액종양내과 임상강사
2010-2011 | 삼성서울병원 혈액종양내과 임상강사
2006-2010 | 삼성서울병원 내과 전공의
2013-2016 | 삼성서울병원 혈액종양내과 임상전임강사
2012-2013 | 삼성서울병원 혈액종양내과 임상강사
2010-2011 | 삼성서울병원 혈액종양내과 임상강사
2006-2010 | 삼성서울병원 내과 전공의
논문
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. Clinical Colorectal Cancer. 2018.9월.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer research and treatment. 2018.9월.
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Translational Oncology. 2018.4월.
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs. 2017.6월.
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer. 2017.6월.
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.. Investigational New Drugs. 2017.4월.
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Translational Oncology. 2016.6월.
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. 2015.11월.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung cancer. 2015.11월.
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist. 2015.11월.
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. International Journal of Biological Markers. 2015.11월.
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. BMC cancer. 2015.10월.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancer. British Journal of Cancer. 2014.7월.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer research and treatment. 2018.9월.
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Translational Oncology. 2018.4월.
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs. 2017.6월.
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer. 2017.6월.
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.. Investigational New Drugs. 2017.4월.
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. Translational Oncology. 2016.6월.
NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget. 2015.11월.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. Lung cancer. 2015.11월.
Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). Oncologist. 2015.11월.
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. International Journal of Biological Markers. 2015.11월.
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. BMC cancer. 2015.10월.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancer. British Journal of Cancer. 2014.7월.
저서
저서 내용이 없습니다.
보도자료
보도자료 내용이 없습니다.
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.